©The Author(s) 2022.
World J Hepatol. Sep 27, 2022; 14(9): 1704-1717
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1704
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1704
Table 1 illustrates the non-alcoholic fatty liver disease activity scoring system
| Group | Definition | Scoring |
| Steatosis | < 5% | 0 |
| 5%-33% | 1 | |
| > 33%-66% | 2 | |
| > 66% | 3 | |
| Lobular inflammation | No foci | 0 |
| < 2 foci per 200× field | 1 | |
| 2-4 foci per 200× field | 2 | |
| > 4 foci per 200× field | 3 | |
| Hepatocyte ballooning | None | 0 |
| Few | 1 | |
| Many | 2 | |
| Fibrosis | No fibrosis | 0 |
| Zone 3 mild perisinusoidal fibrosis | 1a | |
| Zone 3 moderate perisinusoidal fibrosis | 1b | |
| Periportal/portal fibrosis only | 1c | |
| Zone 3+ periportal/portal fibrosis | 2 | |
| Bridging fibrosis | 3 | |
| Cirrhosis | 4 |
- Citation: Mandour MO, El-Hassan M, Elkomi RM, Oben JA. Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future? World J Hepatol 2022; 14(9): 1704-1717
- URL: https://www.wjgnet.com/1948-5182/full/v14/i9/1704.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i9.1704